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Summary Although dry powder inhalers are well established for the delivery of
corticosteroids, the pressurised metered dose inhaler remains the preferred and most
cost effective presentation. To design an HFA solution formulation which matched
marketed CFC products (Pulmicorts and Desonacs DA) two elements of the Chiesi
Modulites system, the addition of a non-volatile component and the actuator orifice
diameter, were varied. These variables, which were shown by in vitro tests to
influence the fine particle dose and its mean particle size in different ways, could be
permuted to give an aerosol cloud with size characteristics very close to the
comparator products. The likelihood that this would confer clinical equivalence is
reinforced by a pharmacokinetic analysis which showed that the chosen HFA solution
formula gave similar systemic absorption from the lung as Pulmicorts. The
equivalence in aerosol characteristics was sustained when the pressurised metered
dose inhalers (pMDIs) were used with spacers. The Chiesi Jets and the AstraZeneca
Nebuhalers, when used with their respective pMDIs, reduced likely oropharyngeal
deposition to the same extent and gave a similar increase in the fine particle dose.
& 2003 Published by Elsevier Ltd.
Introduction
Budesonide, delivered directly to the lung, has
played a major role in establishing corticosteroids
as a mainstay of asthma treatment. Although
introduced as a pressurised metered dose inhaler
(pMDI), its clinical success was greatly influenced
by reformulation as a more efficient multidose dry
powder inhaler (DPI), Turbuhalers. Thorsson et al.1
showed that in this form, the lung deposition was
approximately twice that of the pMDI. Other dry
powder inhalers are now under development,
capitalising on the perceived disadvantages of
Turbuhalers and addressing issues such as the
generation of adequate flow rates, the effect of
inspiration manoeuvre on the dose received by the
patient, cost and patient preference. Using lung
deposition and pharmacokinetics measures, Ball
et al.2 showed that the low-cost Miat Monohalers
could be used in groups of patients, such as
children, unable to inhale maximally through
Turbuhalers. Hirst et al.3 compared lung deposition
from two DPIs, Easyhalers and Turbuhalers, using a
pMDI plus spacer (Nebuhalers) as a reference
standard. Patients preferred the Easyhalers
although the two DPIs were of comparable effi-
ciency. Similar conclusions were drawn by Frew
et al.4 when the novel DPI Airmaxs was compared
to Turbuhalers.
Despite these developments, there remains great
clinical demand for a pMDI delivering budesonide.
pMDIs are small, portable devices used by almost
80% of asthmatic patients. In an extensive review
comparing the effectiveness of inhaler devices, the
findings of Brocklebank et al.5 were that measures
of pulmonary function, symptom scores and ad-
verse event gave no difference in clinical efficacy
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between a pMDI with or without spacer and a DPI
for the delivery of corticosteroids. At present,
therefore, a budesonide pMDI will be the most cost
effective presentation. However, in developing
such a product two issues should be addressed;
the replacement of the chlorofluorocarbon (CFC)
propellants currently used and the perceived
problems patients may experience in coordinating
dose generation and inspiration.
Propellant replacement in pressurised
metered dose inhalers
The general environmental issues related to the
used of CFCs and their replacement hydrofluoroalk-
anes (HFAs) are well known. However, their
replacement in pMDIs has presented the pharma-
ceutical industry with acute problems which relate
to the solubility of drugs and excipients. If the drug
is insoluble in the HFA, it can be reformulated as a
suspension, like the CFC product, with the aim to
yield an aerosol with a similar particle size
distribution of the cloud and a similar pattern of
deposition in the lungs, ultimately eliciting the
same clinical response. At a given dose, the two
formulations will be bioequivalent and transition to
the new formulations will be straightforward. The
problem now to be solved is the stabilisation of the
suspension in circumstances in which the usual
excipients, such as sorbitan trioleate, are inade-
quately soluble in the replacement HFA. Tansey6
describes the addition of ethanol to dissolve oleic
acid, the stabiliser used for salbutamol sulphate in
Airomirs. Cripps et al.7 describe the transition to
stable non-CFC suspension formulations of salbuta-
mol and fluticasone propionate which contain no
excipients other than the propellant. However,
budesonide, like beclometasone dipropionate
(BDP), has a significant solubility in the replace-
ment propellants. A stable suspension product
cannot be devised and the drug must be formulated
as a solution. In a pMDI containing a simple
solution, the size of the particles produced will
be determined by the size of the droplets emerging
from the actuator and the concentration of drug
they contain, factors which combine to form an
ultra-fine cloud. When Leach8 devised the Qvars
solution formulation of BDP, the average particle
size was reduced from 3 to 4 mm observed with the
CFC suspension formulation to only 1.1 mm. More
pervasive delivery to lung allowed the effective
dose to be halved. The advantages and disadvan-
tages of this development have been assessed by
Tashkin.9 Clearly, there is potential for a higher
ratio of therapeutic efficiency to side effects
although the larger amount delivered to the lung
periphery may increase systemic absorption despite
the lower dose. However, major disadvantage of
such formulations is the revision of existing dosage
regimens. A better procedure is to modify the
characteristics of cloud generated by the HFA
formulation to match that of CFC product it is to
replace, thus preserving dosage schedules. The
Chiesi Modulites system, described by Ganderton
et al.,10 may be used to achieve this seamless
transition.
The formulation of a budesonide pMDI
using Modulites
Modulites changes the speed and particle size
of aerosol clouds by permuting four variables: the
non-volatile components of a solution formula,
the actuator orifice geometry, the volume of the
metered solution and the vapour pressure of
the propellant. To achieve a satisfactory match
with suspension formulations, exemplified by Pul-
micorts and Desonac DAs, only two variants, the
non-volatile component and the actuator orifice,
were employed.
An added non-volatile component would increase
the size of aerosol particle once the propellant had
evaporated to values close to those observed in
suspension formulae. Ethanol would be added to
ensure adequate solubility of budesonide. The
observed solubility arising from the interaction of
these constituents, together with water, the ingress
of which arises from the hygroscopic nature of the
chosen propellant HFA134a, is described by the
phase diagram in Fig. 1 which defines the region in
which a homogenous solution is obtained.
The effect of decreasing the aperture of the
actuator orifice is to reduce efflux of the solution
through the metering valve. The speed of the cloud
is reduced without significant change in its particle
size distribution. This reduces oropharyngeal cap-
ture and leads to the delivery of more particles to
the lung.
The demonstration that permutation of these
factors gives a product equivalent to, say, Pulmi-
corts ultimately requires clinical investigation.
However, meaningful in vitro tests can be carried
out to assess a large number of variants which arise
in a Modulites programme. A selected variant can
then be subjected to a pharmacokinetic evaluation
to reinforce selection for clinical evaluation.
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The in vitro evaluation of Modulites
budesonide pMDIs
The aerodynamic diameter of a particle is the
primary determinant of capture in the respiratory
tract. It accommodates the density of the material
and determines the inertial behaviour during flight,
leading to arrest by impaction and sedimentation.
In vitro models simulating these effects are well
established in product development and are ac-
cepted by regulatory authorities. The generated
aerosol is led via a carefully specified inlet or throat
into a multi-stage inertial impactor which divides
the cloud into a number of fractions depending on
aerodynamic diameter. The distribution of drug
mass in these fractions may be tabulated or
expressed as a median with a specified distribution,
mass median aerodynamic diameter (MMAD) and
geometric standard deviation (GSD), respectively. A
fine particle dose may also be derived. This is the
mass of drug in particles less than 5 mm, considered
likely to reach the lung. Material depositing in the
throat is more likely to be captured in the
oropharynx.
In Fig. 2, these principles are applied to
formulations metering 200 mg budesonide and con-
taining different concentrations of glycerol which
modulated the MMAD around the target without
having a significant effect on the fine particle dose.
Opposite effects occur when the actuator orifice
is varied. Fig. 3 shows that when the orifice
diameter is decreased from 0.42 to 0.22mm, the
MMAD is only slightly decreased whereas there is a
large increase in fine particle dose from 30.5 to
85 mg.
These experiments led to the selection of a
formula containing 15% ethanol and 1.3% glycerol in
HFA134a, metering 50 ml of solution containing
200 mg budesonide equipped with an actuator with
an orifice 0.42mm in diameter. A detailed in vitro
deposition pattern of this formula is compared with
Pulmicorts and Desonac DAs in Fig. 4. Simplified
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Figure 1 Phase diagram for HFA 134a, ethanol, water,
1.3470.04w/w% glycerol and budesonide 200 mg/50 ml.
Figure 2 Fine particle dose and MMAD as a function of
glycerol content.
Figure 3 Fine particle dose and MMAD as a function of
actuator orifice diameter.
Figure 4 Drug deposition data of budesonide HFA 200 mg,
Desonacs DA, and Pulmicorts 200 mg.
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data comparing the fine particle dose of the three
products is given in Fig. 5. The data shows that the
Modulites experimental programme has produced
an HFA solution formulation which is a close
match to the established suspension formulations
propelled by CFCs.
Comparative pharmacokinetic evaluation
of budesonide formulations
The development of very sensitive analytical
methods permits quantification of small blood
levels following pulmonary administration. Such
systemic exposure is a useful comparative measure.
For example, Acerbi et al.11 compared the blood
level profile of budesonide epimers following the
administration of 1600 mg budesonide to volunteers
using a solution pMDI equipped with actuators with
0.3 or 0.42mm orifice apertures. The experiments
were conducted with mouth rinsing to ensure
that systemic absorption arose primarily from
the lung. The pharmacokinetic data is show in
Table 1.
Significantly higher AUC values were obtained
with the finer aperture reflecting the higher fine
particle dose and lower MMAD observed in the
in vitro evaluation (Fig. 3). The same experimental
procedure was used to compare the selected HFA
solution formulation with Pulmicorts CFC pMDI and
Pulmicort Turbuhalers.12 Plasma concentrations,
given in Fig. 6, show that when the 0.42 diameter
actuator is used with the HFA formula, a pharma-
cokinetic profile similar to the reference products
is obtained.
The effect of spacers on the delivery of
budesonide
In presenting corticosteroids as pMDIs, the major
disadvantages are coordination of dose generation
with inspiration and the extensive deposition
which occurs in the buccal cavity. The latter may
cause local side effects or, after swallowing,
significant systemic availability. Both disadvantages
may be overcome in large part by the use of
holding chambers or spacers. They are of particular
value with children and with adults when large
doses of corticosteroids are prescribed. Thorsson
and Edsbacker13 evaluated a Pulmicorts pMDI with
and without a Nebuhalers, a large volume spacer,
and showed that the spacer retained about half the
dose and that the dose delivered to the lung
(32.6%) was almost double that of the pMDI alone
(18.3%). This is a very favourable change in the
balance between wanted and unwanted deposition,
oropharyngeal capture being o10% when the
spacer was used. An interesting error in the study
occurred when canisters attached to the spacer
were not shaken between puffs so that contents
were not evenly suspended. This resulted in a
decrease in lung delivery, the systemic availability
via the lung being reduced by a half. Such
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Figure 5 Fine particle dose of budesonide HFA 200 mg,
Desonacs DA and Pulmicorts 200 mg.
Table 1 Budesonide epimers median and (range) plasma levels in six healthy volunteers after a 1600 mg dose.
Parameter BUD HFA 0.30 BUD HFA 0.42 HFA 0.30/HFA 0.42 ratio
22 R epimer Cmax (ng/ml) 1.77 (0.46–2.78) 1.66 (0.5–1.97) 1.07
tmax (h) 0.17 (0.17–0.33) 0.17 (0.17–0.33) F
AUC (ng h/ml) 4.10 (1.44–5.58) 2.20 (1.90–3.43) 1.86
t1/2el (h) 2.21 (1.93–3.07) 2.20 (1.84–2.77) 1.00
22 S epimer Cmax (ng/ml) 1.82 (0.49–3.13) 1.78 (0.58–2.38) 1.02
tmax (h) 0.17 (0.17–0.33) 0.17 (0.17–0.33) F
AUC (ng h/ml) 4.83 (1.52–7.12) 3.27 (2.14–4.82) 1.48
t1/2el (h) 2.35 (1.37–4.32) 2.90 (1.95–3.50) 0.81
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effects are not possible with a Chiesi Modulites
solution formula because no phase separation can
occur.
In Chiesi’s Jets, the spacer, the actuator and the
canister containing the budesonide HFA formula are
integrated to give a compact unit. Using the in vitro
model described above, its effect on the delivered
dose and its particle size distribution is compared
with the pMDI alone in Fig. 7.
Massive oropharyngeal capture from the pMDI,
simulated by throat deposition, is largely trans-
ferred to the Jets and the amount of drug
delivered to the lower stages of the impactor,
which simulates lung delivery, is increased. The
cumulative value of drug r5 mm is 50.5 mg with
Jets compared to 31.3 mg without. The comparison
with Pulmicorts pMDI plus Nebuhalers is made in
Fig. 8. This gives a fine particle dose of 50.5 mg for
budesonide Jets and 52.5 mg Pulmicorts pMDI,
showing how closely the novel HFA formulation
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Figure 6 Budesonide epimers median plasma profile after inhalation of budesonide HFA 0.42, Pulmicorts CFC and
Pulmicorts Turbuhalers in six healthy volunteers.
Figure 7 (a) Drug deposition data of budesonide HFA
200 mg with standard 0.42mm actuator and with Jets
Spacer-Actuator. (b) Fine particle dose of budesonide HFA
200 mg with standard 0.42mm actuator and with Jets
Spacer-Actuator. FPD: mass of drug particles with a
diameter r5 mm.
Figure 8 Fine particle dose of budesonide HFA 200 mg
with Jets and Pulmicorts 200 mg with Nebuhalers.
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matches the Pulmicorts when presented in a
spacer configuration.
Conclusions
Despite the intrinsic fineness of HFA solution pMDIs
and its effect on pulmonary deposition, a strong
case can be made for matching such products to
their coarser CFC suspension counterparts to allow
substitution without change of dose. This can be
achieved using the Chiesi Modulites technology. By
varying the concentration of a non-volatile compo-
nent in the solution and the actuator orifice
diameter, a product was designed which gave an
aerosol which, when assessed in an in vitro model,
was similar in fine particle content and size
distribution to CFC comparator products, suggest-
ing that these products would be clinically equiva-
lent. This is reinforced by a pharmacokinetic
analysis following administration of these products
to volunteers which showed similar systemic
absorption from the lung. This equivalence in
aerosol characteristics was sustained when the
pMDIs were used with spacers. The Chiesi Jets
and the AstraZeneca Nebuhalers reduced likely
oropharyngeal deposition to the same extent and
gave a similar increase in the fine particle dose.
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